Back to Journals » Therapeutics and Clinical Risk Management » Volume 3 » Issue 5

Oblimersen for the treatment of patients with chronic lymphocytic leukemia

Authors Bruce D Cheson

Published 15 November 2007 Volume 2007:3(5) Pages 855—870

Bruce D Cheson

Georgetown University Hospital, The Lombardi Comprehensive Cancer Center, Washington, DC, USA

Abstract: Among adults in Western countries, chronic lymphocytic leukemia (CLL) is the most prevalent form of leukemia. CLL primarily affects the elderly and may be associated with multiple comorbidities. A cure has not been identified, and new treatment options are needed. Expression of Bcl-2 protein is associated with the pathogenesis of CLL and chemotherapy resistance. Oblimersen, a Bcl-2 antisense phosphorothioate oligonucleotide, is being evaluated in patients with CLL and other cancers; trials through Phase III have been completed. In the setting of relapsed/refractory CLL, single-agent oblimersen demonstrates modest activity, whereas the addition of oblimersen to fludarabine/cyclophosphamide significantly improves the rate of complete and nodular partial responses; moreover, these responses are durable and associated with clinical benefit. Oblimersen is more efficacious in relapsed rather than refractory patients. The side effect profile of oblimersen, alone or in combination with standard chemotherapy, is favorable compared with currently available chemotherapies. In the first cycle, an infusion reaction with or without tumor lysis syndrome is uncommon, and transient thrombocytopenia is observed. Catheter-related complications are associated with the need for continuous intravenous infusion of oblimersen over several days; other routes of administration are under clinical investigation. Oblimersen is a promising therapeutic approach for patients with relapsed CLL and should be further evaluated in the front-line setting.

Keywords: chronic lymphocytic leukemia, Bcl-2 antisense, G3139, Genasense®, oblimersen

Download Article [PDF] 

Readers of this article also read:

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency

Schmid ST, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas DA, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla AR

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:687-696

Published Date: 28 September 2012

Assessment of COPD wellness tools for use in primary care: an IPCRG initiative

Cave AJ, Atkinson L, Tsiligianni IG, Kaplan AG

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:447-456

Published Date: 17 July 2012

Exemestane in early breast cancer: a review

Michael Untch, Christian Jackisch

Therapeutics and Clinical Risk Management 2008, 4:1295-1304

Published Date: 5 December 2008

Tadalafil in the treatment of erectile dysfunction

Robert M Coward, Culley C Carson

Therapeutics and Clinical Risk Management 2008, 4:1315-1329

Published Date: 5 December 2008

Effects of treatment with antimicrobial agents on the human colonic microflora

Fatemeh Rafii, John B Sutherland, Carl E Cerniglia

Therapeutics and Clinical Risk Management 2008, 4:1343-1357

Published Date: 5 December 2008

House dust mite control measures in the treatment of asthma

Gillian Vallance, Charles McSharry, Stuart Wood, Neil C Thomson

Therapeutics and Clinical Risk Management 2006, 2:347-354

Published Date: 15 December 2006